Drug Profile
Research programme: BMX protein inhibitors - SuperGen
Latest Information Update: 26 Sep 2011
Price :
$50
*
At a glance
- Originator SuperGen
- Developer Astex Pharmaceuticals
- Class Small molecules
- Mechanism of Action BMX protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer